Edwards Lifesciences Launches Sapien 3 Ultra Resilia Valve Following FDA Approval

Edwards Lifesciences launched Sapien 3 Ultra Resilia valve shortly after the device received FDA approval.

The device combines the company’s Sapien 3 Ultra transcatheter aortic heart valve with its Resilia tissue technology. The tissue has the potential to extend the durability of the Sapien 3 valve, according to the company.

The tissue involves bovine pericardial tissue treated with anti-calcification technology, which addresses one of the primary causes of reintervention following heart valve replacement, the company said.

The device also includes calcium-blocking properties and dry tissue packaging conditions to facilitate ease of use, said Edwards Lifesciences.

The device will be available in the U.S. in limited release in the fourth quarter of this year.